Glenmark becomes the First Pharmaceutical Company to launch Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults
Glenmark Pharmaceuticals Limited an innovation‐driven global pharmaceutical company, became the first to launch Thiazolidinedione Lobeglitazone (Lobeglitazone) in India for the treatment of type 2 diabetes in adults. Marketed under the brand name LOBG; it contains Lobeglitazone (0.5 mg) and to be taken once daily under prescription to improve glycemic control in adult diabetic patients.